| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SLC27A4 |
| Uniprot No | Q6P1M0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-237 aa |
| 活性数据 | MPLTLSTLLQPGRIWTGRRAAEPTPGHNAAWSLSGGGAAVLQAGAETALDPGGILPVVPLLGIWRLALHPGLHQDHQAYLTGDVLVMDELGYLYFRDRTGDTFRWKGENVSTTEVEGTLSRLLDMADVAVYGVEVPGTEGRAGMAAVASPTGNCDLERFAQVLEKELPLYARPIFLRLLPELHKTGTYKFQKTELRKEGFDPAIVKDPLFYLDAQKGRYVPLDQEAYSRIQAGEEKL |
| 分子量 | 51.81 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SLC27A4(FATP4)蛋白的3篇代表性文献信息，按研究方向和内容分类整理：
---
**1. 重组表达与功能研究**
**文献名称**: *"Functional characterization of recombinant human FATP4 in mammalian cell models"*
**作者**: Doe J. et al. (2022)
**摘要**：通过哺乳动物细胞体系(HEK293)成功表达重组人SLC27A4蛋白，验证其对长链脂肪酸的转运活性，并发现其缺失突变会导致细胞脂质积累异常，提示其在脂代谢疾病中的作用。
---
**2. 蛋白纯化与结构分析**
**文献名称**: *"Purification and structural insights of human SLC27A4 using a recombinant bacterial expression system"*
**作者**: Smith R. et al. (2020)
**摘要**：利用大肠杆菌系统高效表达并纯化重组SLC27A4蛋白，通过冷冻电镜解析其跨膜结构域，揭示了脂肪酸结合位点，为设计靶向抑制剂提供结构基础。
---
**3. 病理机制关联研究**
**文献名称**: *"SLC27A4 overexpression exacerbates hepatic insulin resistance via lipid-induced ER stress"*
**作者**: Chen L. et al. (2019)
**摘要**：在小鼠肝细胞中过表达重组SLC27A4.证实其通过增加脂质摄取导致内质网应激，进而加重胰岛素抵抗，提示该蛋白在糖尿病病理中的潜在作用。
---
**额外补充(领域进展)**
**4. 综述：SLC27家族功能与应用**
**文献名称**: *"The SLC27 transporter family: roles in health and disease"*
**作者**: Anderson K. & Black P. (2021)
**摘要**：综述中归纳了SLC27A4在脂肪酸代谢、能量稳态中的作用，并讨论其作为代谢性疾病治疗靶点的潜力，包括重组蛋白在药物筛选中的价值。
---
**说明**：以上文献名为示例，实际引用时需通过PubMed/Google Scholar等平台检索真实研究(可按标题关键词+作者组合查询)。建议关注近年研究(如2020年后)及高影响力期刊(如*Nature Metabolism*, *Journal of Lipid Research*等)。
Recombinant human SLC27A4 protein, also known as fatty acid transport protein 4 (FATP4), is a member of the solute carrier family 27 (SLC27) involved in cellular uptake and metabolism of long-chain fatty acids. Encoded by the SLC27A4 gene, this integral membrane protein is predominantly expressed in tissues with high lipid metabolic activity, such as the small intestine, adipose tissue, and skin. Structurally, it features an N-terminal AMP-binding domain critical for enzymatic activity and transmembrane domains facilitating fatty acid transport.
FATP4 functions as both a transporter and an acyl-CoA synthetase, enabling fatty acid internalization and their subsequent esterification into triglycerides or phospholipids. Its role in maintaining epidermal lipid homeostasis is particularly vital, as mutations in SLC27A4 are linked to ichthyosis prematurity syndrome, a genetic skin disorder characterized by disrupted skin barrier function. Recombinant SLC27A4 is produced using heterologous expression systems (e.g., E. coli or mammalian cells) for functional studies, drug screening, or therapeutic development. Purification typically involves affinity chromatography followed by activity validation through fatty acid uptake assays or enzymatic activity tests. Research on this protein enhances understanding of lipid metabolism disorders and informs potential treatments for related conditions.
×
